Tools commonly used in the Fibromyalgia Diagnosis & Treatment industry for day-to-day tasks and operations.

• Tender point exam
• Blood tests
• Magnetic resonance imaging (MRI)
• X-rays
• Sleep studies
• Physical therapy equipment
• Pain scales
• Cognitive behavioral therapy (CBT) materials
• Medications for pain management
• Acupuncture needles

Common products and services typical of NAICS Code 621511-23, illustrating the main business activities and contributions to the market.

• Fibromyalgia clinics
• Pain management centers
• Rheumatology practices
• Physical therapy practices
• Integrative medicine clinics
• Neurology practices
• Sleep disorder clinics
• Rehabilitation centers
• Wellness centers
• Alternative medicine practices

The specific certifications, permits, licenses, and regulatory compliance requirements within the United States for this industry.

• American Board Of Internal Medicine: Certification for physicians who specialize in internal medicine and its subspecialties, including rheumatology, which is relevant to fibromyalgia diagnosis and treatment. The certification ensures that the physician has met the educational, professional, and ethical standards required for the practice.
• American Board Of Medical Specialties: Certification for physicians who have completed accredited residency training and passed a rigorous exam in their specialty. Rheumatology is a subspecialty of internal medicine, and certification in internal medicine is a prerequisite for certification in rheumatology.
• Clinical Laboratory Improvement Amendments (CLIA): Federal regulatory standards that apply to all clinical laboratory testing performed on humans in the US, including diagnostic tests for fibromyalgia. CLIA certification is required for laboratories that perform these tests and ensures that they meet quality standards for accuracy, reliability, and timeliness.
• College Of American Pathologists (CAP): Accreditation for medical laboratories that meet rigorous standards for quality and safety. CAP accreditation is voluntary but highly regarded and can help laboratories demonstrate their commitment to excellence in fibromyalgia diagnosis and treatment.
• National Board Of Medical Examiners (NBME): Certification for physicians who have completed medical school and passed a series of exams that assess their knowledge and skills. The exams cover a wide range of topics, including rheumatology, which is relevant to fibromyalgia diagnosis and treatment.

A concise historical narrative of NAICS Code 621511-23 covering global milestones and recent developments within the United States.

• The history of Fibromyalgia Diagnosis & Treatment industry dates back to the early 1800s when the first case of fibromyalgia was reported. However, it was not until the 1970s that the condition was recognized as a distinct medical condition. In 1990, the American College of Rheumatology established diagnostic criteria for fibromyalgia, which helped to standardize the diagnosis of the condition. Since then, there have been several notable advancements in the industry, including the development of new medications and therapies to manage the symptoms of fibromyalgia. In the United States, the history of the Fibromyalgia Diagnosis & Treatment industry is closely tied to the history of chronic pain management. In the 1990s, there was a significant increase in the number of prescriptions for opioid painkillers, which led to a rise in opioid addiction and overdose deaths. As a result, there has been a growing interest in non-opioid pain management strategies, including those used to treat fibromyalgia. In recent years, there has been a greater focus on developing personalized treatment plans for patients with fibromyalgia, which take into account their individual symptoms and medical history.

The anticipated future trajectory of the NAICS 621511-23 industry in the USA, offering insights into potential trends, innovations, and challenges expected to shape its landscape.

• Growth Prediction: Stable

  The future outlook for the Fibromyalgia Diagnosis & Treatment industry in the USA is positive. The industry is expected to grow due to the increasing prevalence of fibromyalgia in the country. According to the Centers for Disease Control and Prevention (CDC), an estimated 4 million adults in the US have fibromyalgia, and the number is expected to rise in the coming years. Additionally, advancements in medical technology and research are expected to lead to the development of more effective treatments for fibromyalgia, which will further drive the growth of the industry. However, the industry may face challenges such as the high cost of treatment and the lack of awareness about the condition among the general public.

Recent groundbreaking advancements and milestones in the Fibromyalgia Diagnosis & Treatment industry, reflecting notable innovations that have reshaped its landscape.

• FDA Approval Of the First Drug Specifically for Fibromyalgia: In 2007, the FDA approved pregabalin (Lyrica) as the first drug specifically for the treatment of fibromyalgia. This milestone marked a significant step forward in the treatment of the condition.
• Development Of Non-Pharmacological Treatments: In recent years, there has been a growing interest in non-pharmacological treatments for fibromyalgia, such as cognitive-behavioral therapy, exercise, and acupuncture. These treatments have shown promising results in reducing pain and improving quality of life for fibromyalgia patients.
• Increased Awareness and Education: There has been a growing effort to increase awareness and education about fibromyalgia among healthcare providers and the general public. This has led to earlier diagnosis and treatment of the condition, which can improve outcomes for patients.
• Advancements In Diagnostic Tools: Advancements in medical technology have led to the development of more accurate diagnostic tools for fibromyalgia, such as the use of functional magnetic resonance imaging (fMRI) to identify changes in brain activity associated with the condition.
• Research Into New Treatments: There is ongoing research into new treatments for fibromyalgia, such as the use of cannabinoids and other alternative therapies. These treatments have shown promising results in early studies and may lead to new treatment options for fibromyalgia patients in the future.